Table 1.
Subject Demographics and Baseline Characteristics*
| Characteristic | Placebo Group (n = 62) | SDD Group (n = 51) | p-value |
|---|---|---|---|
| Age (years) | 58.06 (5.73) | 58.62 (5.96) | 0.6 |
| Ethnicity | 0.4 | ||
| Hispanic or Latino | 4 (6%) | 1 (2%) | |
| Not Hispanic or Latino | 58 (94%) | 50 (98%) | |
| Race | >0.9 | ||
| Asian | 2 (3%) | 1 (2%) | |
| African American | 1 (2%) | 1 (2%) | |
| White | 59 (95%) | 49 (96%) | |
| Years postmenopausal | 0.7 | ||
| 5 or fewer years | 22 (35%) | 20 (39%) | |
| More than 5 years | 40 (65%) | 31 (61%) | |
| Smoking status | 0.5 | ||
| Current smoker | 13 (21%) | 10 (20%) | |
| Former smoker | 17 (27%) | 19 (37%) | |
| Never smoker | 32 (52%) | 22 (43%) | |
| Hyperlipidemia† | 55 (89%) | 48 (94%) | 0.5 |
| Hypertension‡ | 12 (19%) | 8 (16%) | 0.6 |
| History of myocardial infarction, angina or stroke | 0 | 0 | |
| Diabetes | 0 | 0 | |
| Body Mass Index (kg/m2) | 28.41 (6.13) | 27.51 (4.38) | 0.4 |
| Number of teeth | 25.63 (2.64) | 25.96 (2.63) | 0.5 |
| Lumbar spine | |||
| Bone mineral density (g/cm2) | 0.91 (0.07) | 0.92 (0.09) | 0.4 |
| T-score | −1.30 (0.67) | −1.20 (0.78) | 0.5 |
| Femoral neck | |||
| Bone mineral density (g/cm2) | 0.71 (0.08) | 0.70 (0.06) | 0.5 |
| T-score | −1.29 (0.68) | −1.37 (0.52) | 0.5 |
| Alveolar bone height (mm) | 3.11 (1.29) | 3.37 (1.50) | 0.2 |
| Manual probing depth (mm) | 3.84 (1.19) | 3.81 (1.12) | 0.7 |
*
Data are expressed as count (%) for categorical variables and mean (standard deviation) for continuous measures. Standard deviation of alveolar bone height and probing depth was estimated using a linear mixed model.
†
Hyperlipidemia is defined as total cholesterol > 200 mg/dL or LDL cholesterol > 100 mg/dL or HDL cholesterol < 50 mg/dL
‡
Hypertension was coded as present for any subject reporting use of a diuretic, calcium channel blocker, beta blocker, or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker